Otonomy begins enrolment in US Phase III trial of OTO-104 to treat Meniere's disease

Otonomy has started patient enrolment in the US Phase III clinical trial of OTO-104, a sustained-exposure formulation of the steroid dexamethasone, to treat Ménière's disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news